← All trials
NCT07105735
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Aug 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Aug 6, 2025
- Last posted
- Aug 6, 2025
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Medical UniversityLead sponsor
- Rui Therapeutics Co., LtdCollaborator
- Nanjing Medical UniversitySponsor investigator
- Nanjing Medical UniversityOfficial
- Allorunning TherapeuticsCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.